GKOS GLAUKOS Corp

Price (delayed)

$96.95

Market cap

$4.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.78

Enterprise value

$5.08B

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, ...

Highlights
The company's gross profit rose by 12% YoY and by 4.1% QoQ
The revenue has grown by 11% YoY and by 3.7% from the previous quarter
GLAUKOS's net income has decreased by 36% YoY and by 4.1% QoQ
GLAUKOS's EPS has decreased by 33% YoY and by 3.3% from the previous quarter

Key stats

What are the main financial stats of GKOS
Market
Shares outstanding
49.47M
Market cap
$4.8B
Enterprise value
$5.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.25
Price to sales (P/S)
14.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.14
Earnings
Revenue
$314.71M
EBIT
-$120.09M
EBITDA
-$82.12M
Free cash flow
-$78.01M
Per share
EPS
-$2.78
Free cash flow per share
-$1.61
Book value per share
$9.46
Revenue per share
$6.5
TBVPS
$12.21
Balance sheet
Total assets
$940.41M
Total liabilities
$478.65M
Debt
$383.74M
Equity
$461.77M
Working capital
$321.45M
Liquidity
Debt to equity
0.83
Current ratio
5.34
Quick ratio
4.61
Net debt/EBITDA
-3.46
Margins
EBITDA margin
-26.1%
Gross margin
76%
Net margin
-42.8%
Operating margin
-40.9%
Efficiency
Return on assets
-14.1%
Return on equity
-27.8%
Return on invested capital
-14.8%
Return on capital employed
-13.9%
Return on sales
-38.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GKOS stock price

How has the GLAUKOS stock price performed over time
Intraday
0.11%
1 week
-4.3%
1 month
13.41%
1 year
99.24%
YTD
21.97%
QTD
2.82%

Financial performance

How have GLAUKOS's revenue and profit performed over time
Revenue
$314.71M
Gross profit
$239.14M
Operating income
-$128.7M
Net income
-$134.66M
Gross margin
76%
Net margin
-42.8%
GKOS's operating income has shrunk by 56% YoY and by 3.9% QoQ
The company's operating margin fell by 41% YoY
GLAUKOS's net income has decreased by 36% YoY and by 4.1% QoQ
The net margin has decreased by 22% YoY

Growth

What is GLAUKOS's growth rate over time

Valuation

What is GLAUKOS stock price valuation
P/E
N/A
P/B
10.25
P/S
14.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.14
GLAUKOS's EPS has decreased by 33% YoY and by 3.3% from the previous quarter
The price to book (P/B) is 80% more than the 5-year quarterly average of 5.7 and 46% more than the last 4 quarters average of 7.0
GLAUKOS's equity has decreased by 13% YoY and by 3.3% QoQ
The P/S is 48% higher than the 5-year quarterly average of 10.1 and 36% higher than the last 4 quarters average of 11.0
The revenue has grown by 11% YoY and by 3.7% from the previous quarter

Efficiency

How efficient is GLAUKOS business performance
The ROE has plunged by 57% YoY and by 8% from the previous quarter
The ROIC is down by 47% year-on-year and by 6% since the previous quarter
The return on assets has declined by 45% year-on-year and by 6% since the previous quarter
GLAUKOS's ROS has decreased by 28% YoY

Dividends

What is GKOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GKOS.

Financial health

How did GLAUKOS financials performed over time
The total assets is 96% greater than the total liabilities
The quick ratio has contracted by 16% YoY and by 10% from the previous quarter
GKOS's current ratio is down by 13% year-on-year and by 10% since the previous quarter
The debt is 17% lower than the equity
The debt to equity has grown by 15% YoY and by 3.8% from the previous quarter
GLAUKOS's equity has decreased by 13% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.